Caliway Biopharmaceuticals (Caliway) will be presenting at the 2024 BIO International Convention to showcase the latest advancements in its lead pipeline candidate, CBL-514. This event, hosted by the Biotechnology Innovation Organization (BIO), brings together over 20,000 biotechnology and pharmaceutical leaders from around the world. Caliway is excited to share its recent progress in Phase 2 studies, which have shown promising results in reducing subcutaneous fat and treating conditions such as Dercum’s disease and cellulite.
Caliway Biopharmaceuticals is a Taiwan-based clinical-stage company focused on developing small-molecule therapeutics for medical aesthetics and inflammatory diseases. Listed on the emerging stock market in Taiwan, Caliway is dedicated to becoming a leader in innovative pharmaceuticals for aesthetic medicine.
The presentation at the BIO International Convention will take place on June 5th at 11:45 a.m. PDT in Company Presentation Theater 2 at the San Diego Convention Center. This is a great opportunity for Caliway to connect with key industry leaders and share its advancements in medical aesthetics.
For more information about Caliway Biopharmaceuticals, please visit their website at http://www.Caliway.com.tw/en. Stay tuned for updates on CBL-514 and other exciting developments from Caliway.
Please note that the information in this article contains forward-looking statements and is subject to risks and uncertainties beyond the control of the Company. The Company does not guarantee future results based on these statements and will provide updates as needed.
For media inquiries or additional information, please contact the company directly.
Source: Caliway Biopharmaceuticals
Image: https://mma.prnewswire.com/media/2397928/Caliway_Biopharmaceuticals_Logo.jpg?p=original
Source link
